Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Novartis's Pelacarsen Sodium?
Pelacarsen Sodium is an antisense oligonucleotide commercialized by Novartis, with a leading Phase II program in Aortic Valve Stenosis. According...
Data Insights
Risk adjusted net present value: What is the current valuation of Novartis's Pelacarsen Sodium?
Pelacarsen Sodium is an antisense oligonucleotide commercialized by Novartis, with a leading Phase III program in Cardiovascular Disease. According to...